

SCIENTIFIC REPORTS



OPEN

Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival

Robin T. Varghese^{1,6}, Sarah Young^{1,2}, Lily Pham^{1,2}, Yanping Liang¹, Kevin J. Pridham^{1,3}, Sujuan Guo¹, Susan Murphy¹, Deborah F. Kelly^{1,2,4,5} & Zhi Sheng^{1,2,5}

Received: 23 October 2017

Accepted: 29 August 2018

Published online: 11 September 2018

Glioblastoma is the most common malignant brain cancer with a dismal prognosis. The difficulty in treating glioblastoma is largely attributed to the lack of effective therapeutic targets. In our previous work, we identified casein kinase 1 ϵ (CK1 ϵ , also known as CSNK1E) as a potential survival factor in glioblastoma. However, how CK1 ϵ controls cell survival remains elusive and whether targeting CK1 ϵ is a possible treatment for glioblastoma requires further investigation. Here we report that CK1 ϵ was expressed at the highest level among six CK1 isoforms in glioblastoma and enriched in high-grade glioma, but not glia cells. Depletion of CK1 ϵ remarkably inhibited the growth of glioblastoma cells and suppressed self-renewal of glioblastoma stem cells, while having limited effect on astrocytes. CK1 ϵ deprivation activated β -catenin and induced apoptosis, which was further counteracted by knockdown of β -catenin. The CK1 ϵ inhibitor IC261, but not PF-4800567, activated β -catenin and blocked the growth of glioblastoma cells and glioblastoma stem cells. Congruently, IC261 elicited a robust growth inhibition of human glioblastoma xenografts in mice. Together, our results demonstrate that CK1 ϵ regulates the survival of glioblastoma cells and glioblastoma stem cells through β -catenin signaling, underscoring the importance of targeting CK1 ϵ as an effective treatment for glioblastoma.

Glioblastoma (GBM) is the most common form of primary malignant cancer in the central nervous system¹. Standard treatments after diagnosis include surgical removal of the bulk tumor, radiation, and chemotherapy. Despite such an aggressive course of treatment, the median survival time of GBM patients has only been extended from 12 months to 14.6 months². Moreover, nearly 90% of GBM patients, if they live longer than two years, develop and succumb to recurrent tumors^{3,4}. As such, the percentage of GBM patients with 5-year survival is only 5.5%¹. Thus, there is an unmet need of effective treatments for this deadly disease.

To search for novel therapeutic targets for GBM, we performed a loss-of-function screen in U87MG human GBM cells using a library of short hairpin RNAs (shRNAs) targeting human kinases⁵. Protein kinases are excellent therapeutic targets as they are often amplified or mutated in cancer and are well fit for structure-based drug design of small molecule inhibitors⁶. From approximately 4,000 shRNAs that target 784 human kinase genes, 20 kinases were identified as potentially important survival factors. One candidate, casein kinase 1 ϵ (CK1 ϵ or CSNK1E), has drawn our attention because multiple shRNAs of CK1 ϵ were found in the screen and the role of CK1 ϵ in GBM remains to be elucidated.

CK1 ϵ is a member of the CK1 gene family, which consists of six isoforms (α , γ 1, γ 2, γ 3, δ , and ϵ). The differential expression levels of CK1 genes in tissues and their capacity to activate downstream targets result in tissue-specific function of each CK1 isoform⁷. While CK1 ϵ has been previously reported as a key modulator of circadian rhythm⁸, its role in cancer cell survival has just emerged. For example, pharmacological inhibition or shRNA-mediated ablation of CK1 ϵ impedes the growth or blocks the survival of pancreatic cancer, sarcoma, breast cancer, colorectal cancer, ovarian cancer, and leukemic cells^{9–14}. However, how CK1 ϵ regulates cancer cell survival is not well understood, partly because of the lack of substrate specificity of CK1 genes¹⁵. It has been reported that CK1 ϵ promotes disease progression in some cancers through different targets such as MYC (MYC proto-oncogene, bHLH transcription factor), AKT (v-akt murine thymoma viral oncogene

¹Virginia Tech Carilion Research Institute, Roanoke, VA, 24016, United States. ²Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA, 24016, United States. ³Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, Blacksburg, VA, 24061, United States. ⁴Department of Biological Sciences, College of Sciences at Virginia Tech, Blacksburg, VA, 24061, United States. ⁵Faculty of Health Science, Virginia Tech, Blacksburg, VA, 24061, United States. ⁶Present address: Edward Via College of Osteopathic Medicine, Blacksburg, VA, 24060, USA. Robin T. Varghese, Sarah Young, Lily Pham, Yanping Liang and Kevin J. Pridham contributed equally. Correspondence and requests for materials should be addressed to Z.S. (email: zhisheng@vtc.vt.edu)

homolog), or β -catenin (catenin beta 1, also known as CTNNB1)^{11,14,16}. Nonetheless, the mechanism underlying CK1 ϵ -regulated cell survival in GBM has not yet been defined and the therapeutic potential of targeting CK1 ϵ requires further investigation.

Here we report that CK1 ϵ was barely detected in glia cells, but highly enriched in GBM. Knockdown of CK1 ϵ induced significant inhibition of cell viability in an array of GBM cell lines, while having a negligible effect on the survival of astrocytes and HEK293 cells. CK1 ϵ deficiency activated β -catenin and, in turn, induced apoptosis and growth inhibition. Moreover, blocking CK1 ϵ diminished the capacity of GBM stem cells (GSCs) to divide. The CK1 ϵ inhibitor IC261, but not PF-4800547, activated β -catenin and mitigated the growth of GBM cells and GSCs *in vitro* and *in vivo*. Our results demonstrate that CK1 ϵ promotes GBM cell survival though attenuating the activity of β -catenin and targeting CK1 ϵ represents an appealing therapeutic option for GBM.

Results

CK1 ϵ is highly expressed in GBM. We first monitored the expression levels of CK1 isoforms through querying online databases. Based on gene expression data from CellMiner, CK1 ϵ mRNA was expressed at a significantly higher level than other CK1 isoforms in four GBM cell lines SF-268, SF-295, SNB-75, and U251 (Fig. 1A). Data from a cDNA microarray study (named Liang Brain) in the Oncomine database showed that fold changes of CK1 α , CK1 ϵ , CK1 γ 2, and CK1 γ 3 in GBM tissues over normal brain tissues were 1.411, 1.746, 1.04, and 1.04, respectively (Fig. 1B). CK1 ϵ levels were higher than other isoforms in GBM patient specimens, consistent with the results in GBM cell lines. To determine the localization and expression levels of CK1 ϵ protein, we queried The Human Protein Atlas database. CK1 ϵ proteins primarily localized to cytoplasm and nucleus in U251 GBM cells (Fig. 1C). Compared to normal cerebral cortex and glia cells, CK1 ϵ proteins were expressed at high levels in high-grade glioma (Fig. 1D). While sample size in some results was small, these data suggest that CK1 ϵ is highly expressed in GBM.

CK1 ϵ is important for GBM cell survival. Next, we sought to verify that CK1 ϵ , a candidate survival kinase gene from our previous RNA interference screen, is important for GBM cell survival through knocking down CK1 ϵ in nine GBM cell lines. As indicated by CK1 ϵ immunoblotting (Fig. 2A, left panel and Fig. S1), CK1 ϵ shRNA decreased CK1 ϵ protein levels by 3–10-fold in nine GBM cell lines tested. Upon CK1 ϵ depletion, the viability of SF-295, U87MG, LN229, SF-268, and U251 cells dropped to less than 60% and that of SNB-75 and LN-18 was even below 10% (Fig. 2A, right panel). These cell lines are hereafter designated as CK1 ϵ shRNA-responsive GBM cells. However, the inhibitory effect on the viability of A172 or T98G cells was only modest (>60%), so they are CK1 ϵ shRNA-nonresponsive GBM cells. In our previous report⁵, we also identified MELK (maternal embryonic leucine zipper kinase) as a survival kinase gene. Because MELK was a known survival factor in GBM¹⁷, we herein used this candidate kinase as a control to compare the effect of CK1 ϵ and MELK on GBM cell survival. We found that MELK deficiency (Fig. 2B, left panel and Fig. S2) only mitigated the viability of U87MG and U251 cells (<60%), while having no or modest effect on the remaining GBM cell line (Fig. 2B, right panel). Our results suggest that CK1 ϵ is important for the survival of multiple GBM cell lines.

To corroborate the above results, we determined the viability of two primary GBM cell lines (VTC-001 and VTC-002), which were recently isolated from patient specimens¹⁸. shRNAs of CK1 ϵ or MELK significantly inhibited the viability of primary VTC-001 and VTC-002 cells (Fig. 2C), consistent with the results from GBM cell lines (Fig. 2A,B). Because CK1 ϵ was more highly expressed in GBM tissues than in normal brain tissues (Fig. 1B,D), we hypothesized that this kinase was not important for the viability of normal cells. As expected, CK1 ϵ deficiency only induced a slight or no decrease of cell viability in astrocytes (Fig. 2D) and HEK293 cells (Fig. S3). Collectively, our results demonstrate that CK1 ϵ is a pivotal survival factor for GBM.

Loss of CK1 ϵ induces apoptosis and growth inhibition through activating β -catenin. To determine whether responses of GBM cell lines to CK1 ϵ depletion depend on levels of CK1 ϵ protein, we performed immunoblotting of CK1 ϵ in GBM cell lines. We found that U87MG, T98G, and SNB-75 expressed higher levels of CK1 ϵ than other cell lines (Fig. 3A). To determine the correlation between cell viability affected by CK1 ϵ depletion and levels of CK1 ϵ , we utilized a linear regression model to reveal the determination coefficient R^2 , which indicates how strong the correlation is. We found that levels of CK1 ϵ protein had no association with the responsiveness of GBM cells to CK1 ϵ depletion ($R^2 = 0.02$; Fig. 3B). In contrast, high levels of MELK protein (Fig. 3C) positively correlated with MELK shRNA-induced growth inhibition ($R^2 = 0.71$; Fig. 3D).

These results led us to hypothesize that the activity, rather than the expression level, of CK1 ϵ is important for GBM cell survival. To test this hypothesis, we measured β -catenin activity in CK1 ϵ -deficient U87MG cells, because β -catenin is one of the major signaling pathways regulated by CK1 genes in cancer cells¹⁹ and is important for gliomagenesis^{20,21}. In the canonical WNT/ β -catenin signaling pathway, CK1 ϵ phosphorylates β -catenin at threonine 41 and serine 45 together with GSK3 β (glycogen synthase kinase 3 β), thereby facilitating β -catenin degradation when WNT ligands are absent^{22,23}. Upon stimulation by WNT ligands, CK1 ϵ facilitates β -catenin activation^{19,24–26}. Hence, whether CK1 ϵ inhibits or activates β -catenin depends upon WNT ligands. Herein, we assumed that CK1 ϵ inactivates β -catenin in GBM cells due to the lack of WNT ligands. Consistent with our expectation, p β -cateninT41S45 was reduced by approximately 3-fold in U87MG cells upon depletion of CK1 ϵ , coinciding with a more than 2-fold increase of non-phosphorylated/active β -catenin (Fig. 4A). In addition to CK1 ϵ shRNA-responsive U87MG cells, we also monitored β -catenin activity in CK1 ϵ shRNA-nonresponsive A172 cells (Fig. 2A, right panel). The ratios of active β -catenin/ β -catenin remained unchanged upon depletion of CK1 ϵ in CK1 ϵ shRNA-nonresponsive A172 cells (Fig. 4B). To confirm that CK1 ϵ depletion does activate β -catenin signaling, we monitored the activity of T-cell factor/lymphoid enhancer factor (TCF/LEF), a major downstream target of activated β -catenin in the nucleus^{19,24–26}. The TOPFlash reporter plasmid contains TCF/LEF binding sites, which are mutated and inactivated in the FOPFlash plasmid²⁷. The reporter activity of both




Figure 1. CK1ε is highly expressed in GBM. (A) mRNA levels of CK1 genes in four GBM cell lines. Data was retrieved from the CellMiner database. The arbitrary copy numbers are shown. Error bars represent standard deviations from four different sets of data. (B) mRNA levels of CK1 genes in normal and GBM tissues. Data was retrieved from the Oncomine database. Fold changes of mRNAs in GBM tissues over mRNAs in normal brain tissues are shown. *P* values determine the statistical significance of mRNA difference between GBM and normal brain tissues. N/A: not available. (C) Immunofluorescence analysis of CK1ε in U251 cells. Green: CK1ε; Blue: nuclei. Data were from The Human Protein Atlas. (D) Immunohistochemical analyses of CK1ε in normal brain tissues and specimens of high-grade glioma. Data were from the Human Protein Atlas. N.D.: not detected.

TOPFlash and FOPFlash was low in NS(non-silencing)-shRNA-treated CK1ε shRNA-responsive U87MG and CK1ε shRNA-nonresponsive A172 cells, as expected (Fig. 4C). Upon treatment of CK1ε shRNA, TOPFlash was activated in U87MG cells, but not in A172 cells. FOPFlash was not activated by CK1ε depletion. These results, consistent with those shown in Fig. 4A,B, demonstrate that CK1ε suppresses β-catenin activity in CK1ε shRNA-responsive GBM cells, but not in CK1ε shRNA-nonresponsive GBM cells.

To gain more insights into the role of CK1ε in GBM cell survival, we measured cell death in CK1ε-deficient GBM cells. We found that c-CASP3 (cleaved caspase 3, an apoptosis marker) significantly increased, whereas levels of LC3B (microtubule-associated proteins 1A/1B light chain 3B; an autophagy marker) decreased, upon CK1ε depletion in CK1ε shRNA-responsive U87MG cells (Fig. 4D). In contrast, no apoptosis was detected in CK1ε shRNA-nonresponsive A172 cells (Fig. 4B, panel c-CASP), congruent with the results shown in Fig. 2A. By using the caspase 3/7 activity assay, we found that CK1ε shRNA activated apoptosis in U87MG and LN-18 cells, but not in A172 cells (Fig. 4E). These results, together with results described previously, demonstrate that CK1ε inhibits apoptosis and promotes cell survival in GBM.




Figure 2. CK1 ϵ is important for GBM cell survival. **(A)** Knockdown of CK1 ϵ in nine GBM cell lines. GBM cells were treated with non-silencing (NS) or CK1 ϵ shRNA. Protein levels of CK1 ϵ in U87MG cells are shown in the left panel. ACTB (β -actin) is the loading control. Band intensities were quantified using Image J. The viability of GBM cell lines was determined by the MTS viability assay and is shown in the right panel. **(B)** Knockdown of MELK in nine GBM cell lines. Left panel: immunoblotting of MELK in U87MG cells. Right panel: cell viability. **(C)** Viability of primary GBM cells upon depletion of CK1 ϵ or MELK. **(D)** Knockdown of CK1 ϵ in astrocytes. Top panel: cell viability; bottom panel: immunoblotting of CK1 ϵ . Full length blots were presented in supplemental materials. * $P < 0.05$; # $P > 0.05$.

Based upon above results, we posited that activated β -catenin was required for apoptosis and growth inhibition induced by CK1 ϵ deficiency. To test this hypothesis, we knocked down both CK1 ϵ and β -catenin in CK1 ϵ shRNA-responsive U87MG cells. Immunoblotting of β -catenin showed that the β -catenin shRNA induced an approximately 20-fold decrease of β -catenin protein (Fig. 4F) when U87MG cells were selected by puromycin (the β -catenin shRNA construct contains a puromycin-resistant gene). Deprivation of β -catenin decreased the levels of growth inhibition and apoptosis induced by CK1 ϵ deficiency (Fig. 4G,H). In contrast, β -catenin shRNA alone had no effect on cell viability and apoptosis. Taken together, CK1 ϵ deprivation induces apoptosis and inhibits cell growth through activating β -catenin signaling in CK1 ϵ shRNA-responsive GBM cells.

CK1 ϵ regulates self-renewal of GSCs. The heterogeneity among different GBM tumors or within a given tumor makes GBM difficult to treat. For example, GBM stem cells (GSCs), a small population of tumor cells that are resistant to current therapies, are thought to be the culprit of GBM formation and disease progression^{28,29}. The identification of survival kinase genes in U87MG cells⁵ prompted us to further investigate the role of these kinases in GSCs. In GS9-6/NOTCH1 GSCs we characterized recently³⁰, 11 shRNAs of survival kinase genes robustly reduced cell viability (<50%; Fig. 5A), among which CK1 ϵ shRNA (highlighted in bold) was one of the candidates with the strongest cytotoxicity. To test whether this inhibitory effect was cell line specific, we knocked




Figure 3. Cell responses to CK1 ϵ depletion do not correlate with levels of CK1 ϵ . **(A)** Immunoblotting of CK1 ϵ in GBM cell lines. ACTB (β -actin) is the loading control. Band intensities were quantified using Image J. **(B)** Correlation of CK1 ϵ protein levels and viability of CK1 ϵ -deficient GBM cell lines. A linear regression model was used to determine the correlation between CK1 ϵ levels and GBM cell viability upon CK1 ϵ depletion (Fig. 2A, right panel). R square is the coefficient of determination. **(C)** Immunoblotting of MELK in GBM cell lines. **(D)** Correlation of MELK protein levels and viability of GBM cell lines. Full length blots were presented in supplemental materials.

down CK1 ϵ in LN-18/GSC, LN229/GSC, and U251/GSC recently established in our laboratory³¹. CK1 ϵ depletion induced a remarkable growth inhibition in these GSCs (Fig. 5B). However, ablation of MELK, a known survival factor of GSC¹⁷, only effectively blocked the growth of U251/GSCs and had no or limited effect on the viability of LN-18/GSCs and LN229/GSCs.

GSCs are different from other differentiated tumor cells because GSCs can self-renew (copy themselves) and differentiate (convert into differentiated cells)³². We then hypothesized that CK1 ϵ regulates GSCs' self-renewal and/or differentiation. To test this hypothesis, we first monitored GSC self-renewal using the sphere formation assay. Knockdown of CK1 ϵ or MELK blocked sphere formation in GS9-6/NOTCH1 GSCs and VTC-001/GSCs (Fig. 5C,D), the latter of which is a patient-derived GSC line from our previous report³¹. CK1 ϵ shRNA inhibited the ability of LN-18/GSCs to self-renew, whereas MELK shRNA failed to do so (Fig. 5D). These results are consistent with the differential effect of CK1 ϵ or MELK shRNA on the viability of LN-18/GSCs (Fig. 5B) and parental CK1 ϵ shRNA-responsive LN-18 cells (Fig. 2A,B). To test GSCs' differentiation, we used an approach in our previous report³³ to monitor serum-induced differentiation in GS9-6/NOTCH1 GSCs. As expected, serum treatment increased the levels of GFAP (glial fibrillary acidic protein, an astrocyte marker) in GS9-6/NOTCH1 GSCs (Fig. 5E). By contrast, depletion of CK1 ϵ failed to induce differentiation of GS9-6/NOTCH1 GSCs, as manifested by no change of GFAP (Fig. 5F). Because β -catenin signaling is also important for the growth of stem cells³⁴, we monitored β -catenin activity and apoptosis in CK1 ϵ -deficient GSCs. Upon CK1 ϵ deprivation, levels of both activated β -catenin and c-CASP3 significantly increased in GS9-6/NOTCH1 GSCs (Fig. 5F). Similar results were obtained in CK1 ϵ -deficient LN229/GSCs (Fig. 5G). Hence, CK1 ϵ determines the capability of GSCs to self-renew and regulates β -catenin activity in GSCs.

The CK1 ϵ inhibitor IC261 suppresses GBM growth *in vitro* and *in vivo*. To explore the therapeutic potential of targeting CK1 ϵ in GBM, we utilized PF-4800567 and IC261, two CK1 ϵ chemical inhibitors reported previously^{35,36}. IC261 yielded a strong growth inhibition in CK1 ϵ shRNA-responsive U87MG cells with an IC50




Figure 4. CK1 ϵ depletion induces apoptosis and growth inhibition through activating β -catenin. **(A)** β -catenin signaling in CK1 ϵ -deficient U87MG cells. Phosphorylated, active, and total β -catenin was assessed using immunoblotting. ACTB (β -actin) is the loading control. Band intensities were quantified using Image J. **(B)** β -catenin signaling in CK1 ϵ -deficient A172 cells. **(C)** Luciferase reporter assay. The TOPFlash plasmid harbors TCF/LEF binding sites and responds to β -catenin activation. FOPFlash contains mutated TCF/LEF binding sites and does not respond to β -catenin activation. **(D)** Immunoblotting of cleaved caspase 3 (c-CASP3, an apoptosis marker) and LC3B (an autophagy marker). **(E)** Caspase 3/7 activity assay. **(F)** Knockdown of β -catenin. U87MG cells were transfected with viruses of NS shRNA or β -catenin shRNA. **(G)** Viability of U87MG cells treated with CK1 ϵ shRNA and/or β -catenin shRNA. **(H)** Immunoblotting of c-CASP3 in U87MG cells upon depletion of CK1 ϵ and/or β -catenin. Error bars represent standard deviations from three independent experiments. Full length blots were presented in supplemental materials. * $P < 0.05$; # $P > 0.05$. N.D.: not detected.

of 1.2 μ M (Fig. 6A). In contrast, PF-4800567 had a modest effect on the viability of U87MG cells with an IC50 of approximately 28.4 μ M (Fig. 6B). We also monitored the cytotoxicity of IC-261 in other GBM cell lines and astrocytes. Surprisingly, IC261 displayed similar growth inhibition in all nine GBM cell lines including CK1 ϵ shRNA-nonresponsive T98G and A172 cells (Figs 2A and 6C). This discrepancy could be explained by the low specificity and selectivity of IC261 in inhibiting CK1 ϵ because this inhibitor also blocks CK1 δ ^{35,37}. Congruent with CK1 ϵ shRNA, IC261 also had no effect on the viability of astrocytes (Fig. 6C). These results demonstrate that CK1 ϵ inhibitors block tumor cell growth, while sparing normal astrocytes. Hence, targeting CK1 ϵ becomes an appealing therapeutic approach for GBM.

PF-4800567 is reported as a selective inhibitor of CK1 ϵ because it blocks CK1 ϵ -controlled activation of circadian rhythm genes³⁶. However, the cytotoxicity of PF-4800567 to GBM cells was not as strong as the non-selective CK1 ϵ inhibitor IC261 (Fig. 6A,B). Given the important role of β -catenin in CK1 ϵ -regulated cell survival (Fig. 4), we postulated that PF-4800567 and IC261 had different capabilities in activating β -catenin. Consistent with our expectation, PF-4800567 increased CK1 ϵ protein levels but decreased the levels of active β -catenin (Fig. 6D, lanes 1–2), whereas IC261 significantly activated β -catenin with a concomitant decrease of CK1 ϵ (Fig. 6D, lanes 3–4). Hence, while PF-4800567 prevents CK1 ϵ from activating circadian rhythm genes³⁶, this drug fails to activate β -catenin and is therefore not as potent as IC261. Future work should aim at identifying CK1 ϵ selective inhibitors that activate β -catenin and induce apoptosis in GBM (see Discussion for details).




Figure 5. CK1 ϵ regulates β -catenin activity and self-renewal of GSCs. **(A)** Viability of GS9-6/NOTCH1 GSCs upon depletion of survival kinase genes. GS9-6/NOTCH1 cells were transduced with viruses of NS shRNA or shRNAs of individual kinase genes from our previous RNA interference screen (ref.⁵). **(B)** Viability of LN-18/GSC, LN229/GSCs, and U251/GSC upon depletion of CK1 ϵ or MELK. **(C)** Images of GS9-6/NOTCH1 spheres treated with NS, CK1 ϵ , or MELK shRNA. Scale bar: 25 μ m. **(D)** Self-renewal assay of VTC-001/GSC, GS9-6/NOTCH1, and LN-18/GSC treated with NS, CK1 ϵ , or MELK shRNA. Percentages of wells with spheres represent capabilities of GSCs to self-renew. **(E)** Differentiation of GS9-6/NOTCH1 cells. Cells were treated with fetal bovine serum (FBS) to induce differentiation, which was indicated by elevated levels of GFAP (an astrocyte marker). **(F)** Immunoblotting of active β -catenin, β -catenin, c-CASP3, NOTCH1, and GFAP in CK1 ϵ -deficient GS9-6/NOTCH1 cells. **(G)** Immunoblotting of active β -catenin, β -catenin, or c-CASP3 in CK1 ϵ -deficient LN229/GSCs. Full length blots were presented in supplemental materials. * $P < 0.05$; # $P > 0.05$.

To explore the therapeutic potential of CK1 ϵ inhibitors in GSCs, we treated GSCs with IC261 and gauged drug responses *in vitro* and *in vivo*. IC261 exhibited a strong cytotoxicity to LN229/GSCs, with an IC₅₀ of 0.5 μ M (Fig. 7A). This drug also robustly decreased the viability of GS9-6/NOTCH1 GSCs (Fig. 7B). Moreover, the growth of LN229/GSC xenograft tumors in immune-deficient mice was substantially inhibited by IC261 (Fig. 7C). The IC261-treated tumors were much smaller than those receiving vehicle DMSO at the end point (Fig. 7D). Further histological analysis confirmed the presence of malignant tumor cells in DMSO treatment group (Fig. 7E, top panel). Intriguingly, a large number of immune cells, but not tumor cells, were found in a tumor-like tissue in a mouse treated with IC261 (Fig. 7E, bottom panel). Hence, inhibiting CK1 ϵ blocks GSCs' growth *in vitro* and *in vivo*.

Taken together, results presented above demonstrate that a non-canonical CK1 ϵ / β -catenin signaling pathway regulates GBM cell survival and targeting this pathway by shRNAs or chemical inhibitors represents an effective GBM treatment (Fig. 8).




Figure 6. The CK1 ϵ inhibitor IC261 blocks GBM cell growth with no effect on astrocytes. **(A)** IC₅₀ of IC261 in U87MG cells. U87MG cells were treated with IC261 at various doses. Viability was determined using the MTS assay and IC₅₀ was calculated using Prism. **(B)** IC₅₀ of PF-4800567 in U87MG cells. **(C)** Cytotoxicity of IC261 in astrocytes and nine GBM cell lines. **(D)** Immunoblotting of CK1 ϵ / β -catenin signaling in U87MG cells treated with IC261 or PF-4800567. Full length blots were presented in supplemental materials. * $P < 0.05$; # $P > 0.05$.

Discussion

The difficulty in treating GBM has motivated brain cancer researchers to search for novel and effective therapeutic options^{38,39}. One current effort for this purpose involves genomic analyses e.g. DNA sequencing, gene expression profiling, as well as bisulfite sequencing of GBM. These large-scale analyses reveal potential genetic alterations that may be important for cancer cell survival, which still requires further investigation in cells and animal models^{40,41}. Targeting known signaling molecules has also been interrogated in the clinic; however, the outcome of these treatments in GBM is still poor^{42,43}. Therefore, new targets are needed. In this report, we demonstrate that a non-canonical CK1 ϵ / β -catenin signaling pathway is essential for the survival of GBM cells as well as the self-renewal of GSCs (Fig. 8). Furthermore, inhibition of CK1 ϵ blocks tumor growth *in vitro* and *in vivo*. Our results have important implications in the development of novel and effective therapies for GBM.

In addition to the identification of a novel therapeutic target for GBM, we also find that depletion of CK1 ϵ activates β -catenin and subsequently induces growth inhibition and apoptosis in GBM and GSCs (Figs 4 and 5). While this finding is contradictory to the oncogenic role of canonical WNT/ β -catenin in glioma^{20,21}, induction of apoptosis by activated β -catenin has been well documented. For instance, over-expression, activation, or stabilization of β -catenin results in either cell death^{44–47} or delayed cell cycle⁴⁸ in a variety of cells including stem cells. The oncogenic role of β -catenin in tumorigenesis including gliomagenesis may solely rely on the activity of canonical WNT/ β -catenin signaling²¹. In our experimental settings, β -catenin is activated by the loss of CK1 ϵ , a negative regulator of β -catenin signaling in the absence of WNT ligands. While no direct evidence was presented in this study, our results suggest a non-canonical CK1 ϵ / β -catenin signaling, in which β -catenin is activated by CK1 ϵ deficiency in the absence of WNT ligands and then transcriptionally activates a different set of genes to induce apoptosis and repress cell growth. Further investigation will elucidate the detailed mechanisms underlying β -catenin-activated apoptosis in GBM.




Figure 7. The CK1 ϵ inhibitor IC261 blocks the growth GSCs *in vitro* and *in vivo*. (A) IC50 of IC261 in LN229/GSCs. (B) Viability of GS9-6/NOTCH1 treated with IC261. (C) Tumor growth in mice. LN229/GSCs were injected subcutaneously into immune-deficient mice followed by treatment of DMSO or IC261 (30 mg/kg). (D) Images of xenograft tumors at the end point. (E) Histological analysis of tumors.

In the present study, we tested two commercially available CK1 ϵ inhibitors IC261 and PF-4800567^{35,36}. However, GBM cells displayed significant difference in responding to these two drugs, with PF-4800567 much less effective than IC261 (Fig. 6). These results are inconsistent with the fact that PF-4800567 is more selective in preventing CK1 ϵ from activating circadian rhythm genes^{35,36}. Nevertheless, our results shown in Fig. 6 suggest that PF-4800567 increases protein levels of CK1 ϵ and concomitantly inactivates β -catenin. Hence, PF-4800567 fails to mimic the effect of CK1 ϵ shRNA on β -catenin activation and the survival of GBM cells. It is therefore possible that CK1 ϵ mediates activities of circadian rhythm genes and β -catenin through independent mechanisms. Because IC261 is an inhibitor of both CK1 ϵ and CK1 δ (36), the lack of specificity in selectively targeting CK1 ϵ may limit its potential application in the clinic to treat GBM even though IC261 effectively blocks tumor growth *in vitro* and *in vivo* (Figs 6 and 7). Future studies will test the possibility of using IC261 as a GBM treatment and will also identify more CK1 ϵ -selective inhibitors that are capable of activating β -catenin and inducing cell death in GBM cells.

Methods

Reagents. Chemical inhibitors of CK1 ϵ include IC261 (Cayman Chemical) and PF-4800567 (Toris Bioscience). All chemicals were dissolved in dimethyl sulfoxide (DMSO) at stock concentrations ranging from 10 to 50 mM. The stock solutions were stored at -80°C . When applied to cells, chemical inhibitors were directly diluted into the culture media at the desired final concentrations. Cells were typically incubated with inhibitors for four to seven days before further analyses.




Figure 8. A noncanonical CK1 ϵ / β -catenin signaling in GBM cell survival.

Cell lines. Nine human GBM cell lines (SF-295, SNB-75, LN-18, LN229, U87MG, SF-268, T98G, A172, and U251) were maintained in Dulbecco's Modified Eagle Medium (DMEM, Life Technologies Corporation) supplemented with 10% fetal bovine serum (FBS; Atlas Biologicals, Inc.), 100 μ g/ml of streptomycin, and 100 IU/ml of penicillin (Gibco). Two primary GBM cell lines (VTC-001 and VTC-002) were maintained in DMEM supplemented with 15% FBS (Peak Serum, Inc.) 100 μ g/ml of streptomycin, and 100 IU/ml of penicillin (Gibco). Human astrocytes were cultured in AGMTM astrocytes growth medium (Lonza). Two primary GBM cell lines were isolated as described previously⁴⁹. Five human GSC lines (VTC-001/GSC, GS9-6/NOTCH1, LN-18/GSC, LN229/GSC, and U251/GSC) were prepared as described previously^{18,31} and were maintained as spheres in stem cell media, which includes DMEM, B-27[®] supplements (Life Technologies Corporation), 20 ng/ml FGF-2 (GenScript), and 20 ng/ml EGF (GenScript).

Analysis of CK1 gene expression. Gene expression analysis was described previously with modifications^{5,50}. The expression data of CK1 genes were retrieved from CellMiner, Oncomine, and The Human Protein Atlas. For the data from CellMiner, the arbitrary copy numbers of each individual CK1 mRNAs in four GBM cell lines were averaged. Error bars represent standard deviation of four sets of data. Fold changes of CK1 mRNAs in GBM over normal brain tissues and *P* values determining the significance of difference between two groups were retrieved from the Oncomine database. Immunofluorescence images of CK1 ϵ in U251 cells and images of immunohistochemical analyses of CK1 ϵ in cerebral cortex and high-grade glioma were obtained from the Human Protein Atlas.

shRNA-mediated gene knockdown. shRNA-mediated knockdown was performed as previously described^{50,51}. shRNAs of CK1 ϵ and MELK (maternal embryonic leucine zipper kinase) were purchased from Thermo Fisher Scientific Inc. The vendor IDs of CK1 ϵ or MELK shRNA were TRCN0000001837 and TRCN0000001645 respectively. The shRNA of β -catenin was purchased from Addgene (cat# 42544). Lentiviruses of individual shRNAs were made according to the manufacturer's instruction. 5×10^5 cells were seeded and transduced with lentiviruses of non-silencing (NS) shRNA or shRNAs of CK1 ϵ , MELK, or β -catenin. Cells were then selected with 0.5–1.0 μ g/ml puromycin for 7 days. Knockdown efficiency was assessed using immunoblotting.

Immunoblotting. Immunoblotting was performed as described in our previous reports^{5,18,30,50,52}. In brief, cells were lysed and total protein was quantified using the Bradford assay (Bio-Rad Laboratories Inc.). An equal amount of total protein (~50 μ g) in each sample was loaded onto an SDS-PAGE gel. After transferring to PVDF membrane, the blot was incubated with antibodies. Antibodies of CK1 ϵ , MELK, β -catenin, phospho- β -cateninThreonine41Serine45 (p β -cateninT41S45), cleaved caspase 3 (c-CASP3), or GFAP (glia fibrillary associated protein), were purchased from Cell Signaling Technology. Antibody of active β -catenin was purchased from EMD Millipore Corporation. Anti-NOTCH1 and anti- β -actin (ACTB) antibodies were purchased from Sigma-Aldrich Co. LLC. Antibodies were diluted as follows: anti-CK1 ϵ (1:500), anti-MELK (1:1000), anti- β -catenin (1:1000), anti-p β -cateninT41S45 (1:200), anti-active β -catenin (1:500), anti-GFAP (1:1000),

anti-c-CASP3 (1:1000), anti-NOTCH1 (1:1000), and anti- β -actin (1:5000). Images were taken using a ChemiDoc MP System (Bio-Rad Laboratories Inc.). The intensities of protein bands were quantified using Image J. The relative intensities were obtained by dividing the intensities of each protein to those of ACTB (loading control). For some experiments, the fold changes of proteins were obtained by dividing the intensities of experiments to those of the control.

MTS viability assay. The MTS viability assay was described previously^{18,50,52}. In brief, 1,000 to 2,000 cells were plated in a 96-well plate. Cells were then treated with DMSO and chemical inhibitors at the indicated doses. After 7 days, cell viability was measured using MTS according to manufacturer's instruction (Promega). The absorbance at 490 nm was measured using a FilterMax F3 microplate reader (Molecular Devices, LLC). Percent cell viability was obtained by dividing the absorbance of treatment groups with those of untreated groups. IC50s were calculated using GraphPad Prism software.

Caspase 3/7 activity assay. Caspase 3/7 activity was monitored using Caspase-Glo[®] 3/7 assay kit (Promega) and modified as previously described⁵⁰. Cells were transduced with viruses containing NS or CK1 ϵ shRNA. After puromycin selection, apoptosis was assessed using the Caspase-Glo[®] 3/7 assay kit per manufacturer's instruction and cell number was determined using the MTS viability assay described above. The luminescence signal and the MTS absorbance were measured using a FilterMax F3 microplate reader. The relative caspase 3/7 activities were obtained by dividing luminescence readings with corresponding MTS absorbance readings. The fold changes of caspase3/7 activity were obtained by dividing relative caspase3/7 activities in CK1 ϵ shRNA-treated cells to those in NS shRNA-treated cells.

Luciferase reporter assay. Luciferase reporter assay was described previously^{53,54}. The β -catenin reporter plasmids M50 Super 8x TOPFlash (abbreviated as TOPFlash) and M51 Super 8x FOPFlash (abbreviated as FOPFlash) were purchased from Addgene. Cells were transduced with viruses containing NS or CK1 ϵ shRNA followed by transient transfection of β -catenin reporter plasmids using Effectene (QIAGEN). Luciferase activity was determined using a luciferase assay kit (Promega) based on manufacturer's instruction. Cell numbers were quantified using the MTS viability assay. The reporter activities were obtained by normalizing the luminescence measurements with corresponding MTS readings.

Stem cell self-renewal assay. Stem cell self-renewal assay (sphere formation assay) was described previously^{18,31}. GSCs were plated in a 96 well plate at cell densities of 50 cells per well. GSCs were transduced with viruses containing NS, CK1 ϵ , or MELK shRNA followed by puromycin selection as described previously. After 2 weeks, wells with spheres were counted and sphere pictures were taken using an inverted microscope with a 10X or 20X lens. Percentages of wells with spheres were obtained by dividing numbers of wells with spheres with numbers of wells plated.

Mouse experiments. Mouse experiments were performed based on methods described previously^{18,50,52,55}. All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Virginia Tech. All animal experiments were performed in accordance with the guidelines and regulations of IACUC. 2×10^5 LN229/GSCs were mixed with Matrigel (Corning) and subcutaneously injected into BALB/c nude mice (Charles River Laboratories). 8 days after cell injection, mice were randomly divided into two groups to receive the following treatments: (1) DMSO; (2) 30 mg/kg IC261. Drugs were administered daily through intraperitoneal injection. During the treatment, tumors were measured daily using a caliper. On day 20, mice were euthanized and tumors were harvested because some tumors in the control group reached 1 cm in diameter. Tumor volumes (mm^3) were calculated using the formula: (length \times width \times width)/2.

Statistical analyses. Student's *t* test was used to determine the difference of means between the control and treatment groups in gene expression analysis and mouse experiments.

Data Availability

All data are available for sharing upon request.

References

- Ostrom, Q. T. *et al.* CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. *Neuro-oncology* **18**, v1–v75, <https://doi.org/10.1093/neuonc/now207> (2016).
- Stupp, R. *et al.* Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* **352**, 987–996, <https://doi.org/10.1056/NEJMoa043330> (2005).
- Weller, M., Cloughesy, T., Perry, J. R. & Wick, W. Standards of care for treatment of recurrent glioblastoma—are we there yet? *Neuro-oncology* **15**, 4–27, <https://doi.org/10.1093/neuonc/nos273> (2013).
- Omuro, A. & DeAngelis, L. M. Glioblastoma and other malignant gliomas: a clinical review. *JAMA: the journal of the American Medical Association* **310**, 1842–1850, <https://doi.org/10.1001/jama.2013.280319> (2013).
- Varghese, R. T. *et al.* Survival kinase genes present prognostic significance in glioblastoma. *Oncotarget* **7**, 20140–20151, <https://doi.org/10.18632/oncotarget.7917> (2016).
- Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer* **9**, 28–39, <https://doi.org/10.1038/nrc2559> (2009).
- Schitteck, B. & Sinnberg, T. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. *Mol Cancer* **13**, 231, <https://doi.org/10.1186/1476-4598-13-231> (2014).
- Yang, Y., Xu, T., Zhang, Y. & Qin, X. Molecular basis for the regulation of the circadian clock kinases CK1delta and CK1epsilon. *Cell Signal* **31**, 58–65, <https://doi.org/10.1016/j.cellsig.2016.12.010> (2017).
- Brockschmidt, C. *et al.* Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 *in vitro* and *in vivo*. *Gut* **57**, 799–806, <https://doi.org/10.1136/gut.2007.123695> (2008).

10. Yang, W. S. & Stockwell, B. R. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. *Genome Biol* **9**, R92, <https://doi.org/10.1186/gb-2008-9-6-r92> (2008).
11. Kim, S. Y. *et al.* CK1epsilon is required for breast cancers dependent on beta-catenin activity. *Plos One* **5**, e8979, <https://doi.org/10.1371/journal.pone.0008979> (2010).
12. Ye, L. C. *et al.* Knockdown of Casein Kinase 1e Inhibits Cell Proliferation and Invasion of Colorectal Cancer Cells via Inhibition of the Wnt/beta-Catenin Signaling. *J Biol Regul Homeost Agents* **29**, 307–315 (2015).
13. Rodriguez, N. *et al.* Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells. *EMBO molecular medicine* **4**, 952–963, <https://doi.org/10.1002/emmm.201101094> (2012).
14. Deng, C. *et al.* Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kdelta and CK1epsilon in hematological malignancies. *Blood* **129**, 88–99, <https://doi.org/10.1182/blood-2016-08-731240> (2017).
15. Knippschild, U. *et al.* The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. *Front Oncol* **4**, 96, <https://doi.org/10.3389/fonc.2014.00096> (2014).
16. Zhang, S. *et al.* ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. *Plos One* **7**, e31127, <https://doi.org/10.1371/journal.pone.0031127> (2012).
17. Nakano, I. *et al.* Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. *J Neurosci Res* **86**, 48–60, <https://doi.org/10.1002/jnr.21471> (2008).
18. Murphy, S. F. *et al.* Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. *Cancer Res* **76**, 139–149, <https://doi.org/10.1158/0008-5472.CAN-15-1286> (2016).
19. Cruciat, C. M. Casein kinase I and Wnt/beta-catenin signaling. *Current opinion in cell biology* **31C**, 46–55, <https://doi.org/10.1016/j.ceb.2014.08.003> (2014).
20. Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. *Nature reviews. Cancer* **13**, 11–26, <https://doi.org/10.1038/nrc3419> (2013).
21. Kaur, N. *et al.* Wnt3a mediated activation of Wnt/beta-catenin signaling promotes tumor progression in glioblastoma. *Molecular and cellular neurosciences* **54**, 44–57, <https://doi.org/10.1016/j.mcn.2013.01.001> (2013).
22. Amit, S. *et al.* Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. *Genes Dev* **16**, 1066–1076, <https://doi.org/10.1101/gad.230302> (2002).
23. Yost, C. *et al.* The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in *Xenopus* embryos by glycogen synthase kinase 3. *Genes Dev* **10**, 1443–1454 (1996).
24. Knippschild, U. *et al.* The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. *Onkologie* **28**, 508–514, <https://doi.org/10.1159/000087137> (2005).
25. Price, M. A. C. K. I. there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. *Genes Dev* **20**, 399–410, <https://doi.org/10.1101/gad.1394306> (2006).
26. Cheong, J. K. & Virshup, D. M. Casein kinase 1: Complexity in the family. *Int J Biochem Cell Biol* **43**, 465–469, <https://doi.org/10.1016/j.biocel.2010.12.004> (2011).
27. Veeman, M. T., Slusarski, D. C., Kaykas, A., Louie, S. H. & Moon, R. T. Zebrafish prickles, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. *Current biology: CB* **13**, 680–685 (2003).
28. Osuka, S. & Van Meir, E. G. Overcoming therapeutic resistance in glioblastoma: the way forward. *J Clin Invest* **127**, 415–426, <https://doi.org/10.1172/JCI89587> (2017).
29. Parker, N. R., Khong, P., Parkinson, J. F., Howell, V. M. & Wheeler, H. R. Molecular heterogeneity in glioblastoma: potential clinical implications. *Frontiers in oncology* **5**, 55, <https://doi.org/10.3389/fonc.2015.00055> (2015).
30. Pohlmann, E. S. *et al.* Real-time visualization of nanoparticles interacting with glioblastoma stem cells. *Nano letters* **15**, 2329–2335, <https://doi.org/10.1021/nl504481k> (2015).
31. Kanabur, P. *et al.* Patient-derived glioblastoma stem cells respond differentially to targeted therapies. *Oncotarget* **7**, 86406–86419, <https://doi.org/10.18632/oncotarget.13415> (2016).
32. Dirks, P. B. Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* **363**, 139–152, <https://doi.org/10.1098/rstb.2006.2017> (2008).
33. Sheng, Z., Chang, S. B. & Chirico, W. J. Expression and purification of a biologically active basic fibroblast growth factor fusion protein. *Protein Expr Purif* **27**, 267–271 (2003).
34. Ring, A., Kim, Y. M. & Kahn, M. Wnt/catenin signaling in adult stem cell physiology and disease. *Stem Cell Rev* **10**, 512–525, <https://doi.org/10.1007/s12015-014-9515-2> (2014).
35. Behrend, L. *et al.* IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. *Oncogene* **19**, 5303–5313, <https://doi.org/10.1038/sj.onc.1203939> (2000).
36. Walton, K. M. *et al.* Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. *The Journal of pharmacology and experimental therapeutics* **330**, 430–439, <https://doi.org/10.1124/jpet.109.151415> (2009).
37. Cheong, J. K. *et al.* IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/varepsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation. *Oncogene* **30**, 2558–2569, <https://doi.org/10.1038/nc.2010.627> (2011).
38. Pridham, K. J., Varghese, R. T. & Sheng, Z. The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma. *Front Oncol* **7**, 312, <https://doi.org/10.3389/fonc.2017.00312> (2017).
39. Grek, C. L. *et al.* Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. *Curr Opin Pharmacol* **41**, 79–88, <https://doi.org/10.1016/j.coph.2018.05.002> (2018).
40. Chen, J., McKay, R. M. & Parada, L. F. Malignant glioma: lessons from genomics, mouse models, and stem cells. *Cell* **149**, 36–47, <https://doi.org/10.1016/j.cell.2012.03.009> (2012).
41. Riddick, G. & Fine, H. A. Integration and analysis of genome-scale data from gliomas. *Nature reviews. Neurology* **7**, 439–450, <https://doi.org/10.1038/nrneuro.2011.100> (2011).
42. Wen, P. Y. *et al.* Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. *Neuro-oncology* **16**, 567–578, <https://doi.org/10.1093/neuonc/not247> (2014).
43. Den, R. B. *et al.* A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. *Int J Radiat Oncol Biol Phys* **85**, 321–328, <https://doi.org/10.1016/j.ijrobp.2012.04.017> (2013).
44. Kim, K., Pang, K. M., Evans, M. & Hay, E. D. Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. *Mol Biol Cell* **11**, 3509–3523 (2000).
45. Ming, M. *et al.* Activation of Wnt/beta-catenin protein signaling induces mitochondria-mediated apoptosis in hematopoietic progenitor cells. *J Biol Chem* **287**, 22683–22690, <https://doi.org/10.1074/jbc.M112.342089> (2012).
46. Edlund, S. *et al.* Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. *Mol Cell Biol* **25**, 1475–1488, <https://doi.org/10.1128/MCB.25.4.1475-1488.2005> (2005).
47. Zimmerman, Z. F., Kulikauskas, R. M., Bomsztyk, K., Moon, R. T. & Chien, A. J. Activation of Wnt/beta-catenin signaling increases apoptosis in melanoma cells treated with trail. *Plos One* **8**, e69593, <https://doi.org/10.1371/journal.pone.0069593> (2013).
48. Kimura, T. *et al.* The stabilization of beta-catenin leads to impaired primordial germ cell development via aberrant cell cycle progression. *Dev Biol* **300**, 545–553, <https://doi.org/10.1016/j.ydbio.2006.06.038> (2006).

49. Adams, M. N. *et al.* EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. *Oncogene* **34**, 1375–1383, <https://doi.org/10.1038/onc.2014.88> (2015).
50. Pridham, K. J. *et al.* PIK3CB/p110beta is a selective survival factor for glioblastoma. *Neuro Oncol* **20**, 494–505, <https://doi.org/10.1093/neuonc/nox181> (2018).
51. Guo, S. *et al.* A large-scale RNA interference screen identifies genes that regulate autophagy at different stages. *Sci Rep* **8**, 2822, <https://doi.org/10.1038/s41598-018-21106-5> (2018).
52. Guo, S. *et al.* A rapid and high content assay that measures cyto-ID-stained autophagic compartments and estimates autophagy flux with potential clinical applications. *Autophagy* **11**, 560–572, <https://doi.org/10.1080/15548627.2015.1017181> (2015).
53. Sheng, Z., Wang, S. Z. & Green, M. R. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. *Embo J* **28**, 866–876, <https://doi.org/10.1038/emboj.2009.35> (2009).
54. Sheng, Z. *et al.* A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. *Nature medicine* **16**, 671–677, <https://doi.org/10.1038/nm.2158> (2010).
55. Li, T. *et al.* A New Interleukin-13 Amino-Coated Gadolinium Metallofullerene Nanoparticle for Targeted MRI Detection of Glioblastoma Tumor Cells. *Journal of the American Chemical Society* **137**, 7881–7888, <https://doi.org/10.1021/jacs.5b03991> (2015).

Acknowledgements

We thank all members in the Sheng and Kelly lab for critical discussion of this study. This work was supported by the Startup Funds provided to Z.S. by the Virginia Tech Carilion Research Institute, the Mentorship Funds provided to Z.S. by the Virginia Tech Carilion School of Medicine, and the summer research fellowship provided to S.Y. by American Brain Tumor Association.

Author Contributions

Z.S. conceived the project. Z.S., K.J.P. and R.T.V. wrote and edited the manuscript. R.T.V., S.Y., L.P., Y.L., S.G., K.J.P. and S.M. performed all the experiments. D.F.K. helped data analysis and provided reagents.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-018-31864-x>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018